Perha Pharmaceuticals

Perha Pharmaceuticals is a biotech company focusing on the development of innovative, low molecular weight kinase inhibitors to address cognitive disorders associated with Down syndrome (DS) and Alzheimer's disease (AD), as well as hearing loss induced by ototoxic products. Founded in April 2019 by Dr. Laurent MEIJER and Dr. Philippe de LAVENNE, the company has garnered attention with its groundbreaking research. Notably, Dr. Meijer's expertise in the study of protein kinases and their inhibitors at CNRS adds a strong research foundation to the startup. With a focus on two main programs, Perha Pharma aims to correct cognitive deficits associated with Down syndrome by targeting the DYRK1A protein kinase. They have identified pharmacological inhibitors derived from Leucettamine B, extracted from the Leucetta microraphis marine sponge, which have shown promise in preclinical studies. Additionally, the company is working on preventing hearing loss induced by ototoxic drugs or noise, and has received a €2.50M grant investment at 23 March 2022 from the European Innovation Council to support its pioneering research. Being headquartered in France, Perha Pharmaceuticals not only demonstrates potential in addressing critical unmet medical needs but also exhibits a strong foundation for sustained growth in the Biopharma, Biotechnology, and Health Care industries. With its compelling research focus and recent investment, Perha Pharmaceuticals is poised to make significant strides in addressing these challenging health conditions.